AN2 Therapeutics, Inc. Share Price & Technical Analysis
ANTX · $4.21 (+3.44%)
Healthcare / Biotechnology
$4.21
+3.44%
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN153…
Price chart
Seasonality
Jun has 2 positive and 2 negative years (last 5 years shown)
-5% return in Jun, 21% avg return in past 3 year Jun month.
229% return in 2026, 4% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | 209% | 31% | -7% | -5% | – | – | – | – | – | – | 229% |
| 25 | -21% | 0% | 27% | -14% | -8% | 0% | 10% | 0% | 18% | -8% | -8% | 10% | 5% |
| 24 | -4% | -84% | 7% | -29% | -17% | 10% | 14% | -58% | 0% | 0% | 55% | -12% | -120% |
| 23 | 28% | -2% | -12% | -21% | -28% | 52% | -10% | 81% | 8% | -11% | 24% | 16% | 125% |
| 22 | – | – | -11% | 1% | -9% | -49% | 12% | 104% | 2% | -20% | -32% | -4% | -8% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Neutral
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$150.73M
P/E ratio
—
52W high
$6.91
52W low
$1.00
Volume
22,839
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is AN2 Therapeutics, Inc. share price today?
- AN2 Therapeutics, Inc. (ANTX) last traded around $4.21 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ANTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ANTX. Download the app for real-time alerts.
- How can I analyze AN2 Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.